Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Advantages and disadvantages of mergers and acquisitions
Advantages and disadvantages of mergers and acquisitions
Advantages and disadvantages of mergers and acquisitions
Don’t take our word for it - see why 10 million students trust us with their essay needs.
External Environment Analysis Economy Merck & Co. has to be aware of the economy as with any industry. Within the recession, more and more were looking towards generic substitutes. This can at times not be a problem with patents. However, once a patent is up, a competitor who develops generic versions of Merck’s products becomes a low-cost competitor. However, during the recession from 2008 – 2009, Merck didn’t see any drop in sales. Actually, they were able to keep a continual increase in sales and net income. Socio-Culture Merck has not had to worry about much socio-culture shifts. As long as people need prescription drugs, they will have a consumer. There has been a slight shift in some who are wanting more natural remedies. However, …show more content…
They are missing out on opportunities that exist externally. It is time for the mindset of the company to evolve and understand that not all great ideas will be developed internally. In order to jump back to being the leading pharmaceutical company, they will have to open their doors to external pharmaceutical innovation. Stakeholder Identification A decision on whether or not an open innovation strategy is implement effects several stakeholders. First of all, it effects the stakeholders who are shareholders. Shareholders could be missing out on increased profits because the culture and organization of the company has become stubborn. Researchers who work at Merck are also stakeholders who are affected by this decision. They could possible lose jobs if Merck does employ an open innovation strategy and finds it more successful than its current innovation strategy. However, it could also develop more for them to work with and create more success. Varying ideas may be brought which works well with current ideas set in motion my Merck researchers. With the help of external ideas, they may be able to improve or create new …show more content…
It will allow more opportunities for the Merck & Co. to innovate from. Not all great ideas are being generated within Merck and this strategy will allow us access to those other great ideas. Open innovation will help Merck jump back in the lead of developing the larger number of new pharmaceutical drugs. They have already dipped their toe in with the “reverse-merger” with Schering-Plough which was great way to introduce the idea to the organization and culture within Merck. This course of action is the most ethical because it allows the company to maintain its core strategy of differentiation. It will also help continue the reputation of being innovative by supplying more ideas to work with within the R&D department. It will create more possible drug choices for consumers and profits for the company to enjoy, especially shareholders. An external idea could help produce the next Nobel Prize for the R&D
However, RLK’s competitors are downsizing and outsourcing R&D and exploiting on the cost advantages. If RLK decides to invest more money into R&D and should the new product stall on launch, they face the danger of becoming bankrupt.
...ll help the company in selling generic drugs and provide affordable medications to its customer base.
Main Issue In 2000, Rich Kender, Vice President of Financial Evaluation and Analysis at Merck & Company was discussing the opportunity of investing in licensing, manufacturing and marketing of Davanrik, a drug originally developed to treat depression by LAB Pharmaceuticals. LAB proposed to sell the rights of all the future profits made from the successful launch of Davanrik at the cost of an initial fee, royalty payments and additional payments as the drug completed each stage of the approval process. Merck & Company's organizational goal is to constantly refresh its drug development portfolio and reach as many customers as possible during the patented period. So there was not only the potential of financial gain or quantitative aspect of the offer, but also the qualitative value which will be added by getting better positioning in the risky pharmaceutical industry.
I think it is wise for the board of executives to take an active role in coming up with a system to evaluate their products. This evaluation system is considered a function strategy. In our text, it tells us that functional strategies consist of production procedures, advertising, product research, product development, personnel, economic, and support. (Coulter, K. 2013, p. 7) Due to the fact that Clorox has a wide range of products that are very diverse, it is important for them to evaluate them based on the current market. This strategy has allowed the company to evaluate the value of the products before resulting in a price increase or decrease. Clorox made a competitive strategy when they decided to go green. This was during the period when the company was going through leadership shift and the CEO thought
Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.
It is as a result of acquiring distinct competitive advantages that CEMEX was able ...
... global marketplace, it is also essential that Johnson & Johnson focuses on the critical drivers of their future growth: to create value through innovation, to extend their global reach, with local focus, to execute with excellence in everything it does and to inspire leadership with purpose among the people who carry on the Johnson & Johnson legacy.
Over the past years, the U.S. pharmaceutical industry R&D spending has increased at a rapid rate. Costs have been relatively stable in the preclinical phase, but have risen dramatically in the clinical phase both in terms of direct costs incurred and in time required to complete the trials.2 DiMasi reasoning for the increase in costs is from the focused development for chronic and degenerative conditions that require more costly studies for efficacy and larger clinical trial sizes.2 Some pharmaceutical companies found ways to fill their pipelines through: 1. mergers and acquisitions, 2. in-licensing new compounds, and 3. form strategic alliances and partnerships with other companies. Forming a partnership does help developing a product or drug...
When a drug does make it to market and is successful, companies need to make up for the money spent in development as well as the cost of drugs which did not make it to market. After all investments are taken care of, there is still the need for profit. Some are concerned that if the United States government implements control over prescription drug costs, then private firms will be less motivated to invest in pharmaceutical development, fearing they will not make their investment back. This would supply pharmaceutical companies with less finances for the research and development process. According to the information collected by Abbott and Vernon, a drop in the price of pharmaceuticals would result in significant loss in investment in research and development (Abbott and Vernon).
Other companies cannot replicate the drug and therefore they are forced to either wait until the patent expires or they must find an alternative drug that carries out the same purpose.... ... middle of paper ... ... It is clear to see that there are many pros and cons to patents in the pharmaceutical industry.
Another recommendation for Boston Scientific is to pursue a differentiation strategy instead of a cost-based leadership strategy. The oligopolistic nature of the industry and opportunities for innovation create an ideal situation for differentiation. This strategy is also dependent upon Boston Scientific acquiring and maintaining a plethora of patents. By using these patents, Boston Scientific would be able to create a distinct, innovative product that consumers would be willing to pay a higher amount for. Consumers would be less price-sensitive if Boston Scientific’s products were unrivaled and unique. Additionally, creating a technologically superior device could lead to a sustainable competitive advantage for Boston Scientific. Due to the
Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well as the opportunities and threats that it faces, its strategic priorities and the acquisition strategy that it might follow.
Many new players entered the market copying the same techniques for growth as Teva to capture a significant market share by offering low prices due to their low cost strategies. The entry of these players made the industry intense with tough competition, low profit margins and collapsed prices. The segment of drug industry where Teva had to come up with innovative drugs demands to invest high capital on R&D that was in billions for a single drug could potentially lower the growth and revenues for Teva and could push the company into serious trouble. Analysis To build some effective and real world alternatives and recommendations to Teva Pharmaceuticals, we will conduct the following analysis to understand the external and internal situation of the company. Internal and External Analysis SWOT Analysis (Exhibit 1) Strengths:
The case under analysis, Eli Lilly & Company, will be covering the positives and negatives with regards to the business situation and strategy of Eli Lilly. One of the major pharmaceutical and health care companies in its industry, Lilly focused its efforts on the areas of "drug research, development, and marketed to the following areas: neuroscience, endocrinology, oncology, cardiovascular disease, and women's health." Having made a strong comeback in the 1990's due to its remarkably successful antidepressant Prozac, was now facing a potential loss in profits with its patent soon to expire. The problem was not only the soon to expire patent on Prozac, but the fact that Prozac accounted for as much as 30% of total revenue was the reality Eli Lilly now faced. (Pearce & Robinson, 34-1)
Open innovation opens the doors for a vast array of ideas and suggestions that can help an organization succeed in being innovative. This will allow the organization to hold a competitive advantage when compared to their competition. Organizations who understand the importance of managing technological innovation will have an easier time succeeding than those organizations who feel they are safe and put innovation on the back burner. Managing technological innovation is essential in this day and age, where technology is advancing at a faster than